TW202317514A - 新穎方法 - Google Patents

新穎方法 Download PDF

Info

Publication number
TW202317514A
TW202317514A TW111123528A TW111123528A TW202317514A TW 202317514 A TW202317514 A TW 202317514A TW 111123528 A TW111123528 A TW 111123528A TW 111123528 A TW111123528 A TW 111123528A TW 202317514 A TW202317514 A TW 202317514A
Authority
TW
Taiwan
Prior art keywords
piperidine
typically
solvent
group
protected
Prior art date
Application number
TW111123528A
Other languages
English (en)
Chinese (zh)
Inventor
保羅 弗瑞瑟
捷達 帕爾古納
瑪萊許 巴拉沙
喬瑟芬 E F 辛誇爾
瑞吉斯 J G 蒙迪爾
派洛 托莎蒂
Original Assignee
瑞士商F 霍夫曼拉羅氏股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商F 霍夫曼拉羅氏股份公司 filed Critical 瑞士商F 霍夫曼拉羅氏股份公司
Publication of TW202317514A publication Critical patent/TW202317514A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/40Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111123528A 2021-06-23 2022-06-23 新穎方法 TW202317514A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202141028180 2021-06-23
IN202141028180 2021-06-23

Publications (1)

Publication Number Publication Date
TW202317514A true TW202317514A (zh) 2023-05-01

Family

ID=82458485

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111123528A TW202317514A (zh) 2021-06-23 2022-06-23 新穎方法

Country Status (12)

Country Link
US (1) US20240150291A1 (https=)
EP (1) EP4359385A2 (https=)
JP (1) JP2024524215A (https=)
KR (1) KR20240024842A (https=)
CN (1) CN118019727A (https=)
AR (1) AR126215A1 (https=)
AU (1) AU2022300325A1 (https=)
CA (1) CA3219597A1 (https=)
IL (1) IL308071A (https=)
MX (1) MX2023014547A (https=)
TW (1) TW202317514A (https=)
WO (1) WO2022268935A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI876271B (zh) * 2022-02-15 2025-03-11 瑞士商赫孚孟拉羅股份公司 新穎方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024133610A1 (en) * 2022-12-23 2024-06-27 F. Hoffmann-La Roche Ag Proccesses for the preparation of an nlrp3 inhibitor
IL325043A (en) 2023-08-16 2026-01-01 Hoffmann La Roche Process for the preparation of 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indecen-4-yl)carbamoyl)piperidine-4-sulfonamide
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69727837T2 (de) * 1997-05-02 2004-12-30 Dr. Reddy's Research Foundation, Hyderabad Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel
HUP0303204A3 (en) * 2000-11-16 2010-04-28 Sankyo Co 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
WO2002100833A1 (en) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
US7220735B2 (en) * 2002-04-18 2007-05-22 Schering Corporation Benzimidazolone histamine H3 antagonists
TW200524865A (en) * 2003-10-08 2005-08-01 Nicholas Piramal India Ltd Fibrinogen receptor antagonists and their use
DOP2006000009A (es) * 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
JP5508027B2 (ja) * 2007-02-22 2014-05-28 メルク セローノ ソシエテ アノニム キノキサリン化合物及びその使用
JP5898962B2 (ja) * 2012-01-11 2016-04-06 東京応化工業株式会社 レジスト組成物及びレジストパターン形成方法
WO2017095758A1 (en) * 2015-12-01 2017-06-08 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver x receptor beta agonists, compositions, and their use
US11465992B2 (en) * 2017-07-07 2022-10-11 Inflazome Limited Sulfonamide carboxamide compounds
GB201712282D0 (en) * 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
EP3668861A1 (en) * 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3773576A4 (en) * 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
CR20200588A (es) * 2018-05-04 2021-06-24 Inflazome Ltd Compuestos novedosos
CA3113573A1 (en) * 2018-09-21 2020-03-26 Novartis Ag Isoxazole carboxamide compounds and uses thereof
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
GB201819083D0 (en) * 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
WO2020157069A1 (en) * 2019-01-28 2020-08-06 NodThera Limited Amino heterocyclic compounds and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI876271B (zh) * 2022-02-15 2025-03-11 瑞士商赫孚孟拉羅股份公司 新穎方法

Also Published As

Publication number Publication date
WO2022268935A3 (en) 2023-02-02
IL308071A (en) 2023-12-01
EP4359385A2 (en) 2024-05-01
US20240150291A1 (en) 2024-05-09
CN118019727A (zh) 2024-05-10
AR126215A1 (es) 2023-09-27
KR20240024842A (ko) 2024-02-26
AU2022300325A8 (en) 2023-11-16
AU2022300325A1 (en) 2023-11-02
WO2022268935A2 (en) 2022-12-29
CA3219597A1 (en) 2022-12-29
JP2024524215A (ja) 2024-07-05
MX2023014547A (es) 2024-04-29

Similar Documents

Publication Publication Date Title
TW202317514A (zh) 新穎方法
AU2021212669B2 (en) GLP-1R modulating compounds
JP2025527298A (ja) 三環式化合物及びその医薬用途
JP6746613B2 (ja) ウレア誘導体、またはその薬理学的に許容される塩
KR20200057705A (ko) 리보시클립 및 그의 염의 제조를 위한 개선된 방법
TW202547822A (zh) 4-纈胺醯氧基丁酸的合成方法
JP2024123202A (ja) 大環状化合物とその使用
WO2022214645A1 (en) Processes and intermediates for the preparation of relugolix
CN106220624A (zh) 阿哌沙班合成中的关键中间体和杂质:阿哌沙班二醇酯
KR102477924B1 (ko) 인돌 카르복스아미드 화합물을 제조하는 방법
TW202448866A (zh) 治療性化合物
US20240400516A1 (en) Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivataives
HK1225388A1 (zh) 通过环化2-(氨基乙氧基)苯甲酸衍生物制备3,4-二氢-1,4-苯并氧氮杂环庚三烯-5(2h)-酮衍生物
EP2004655A1 (en) Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4 l)-1-oxo-2,6-dihydro-1h-ý1,2¨diazepinoý4,5,6-cd¨indol-8-yl)acetamide
CN109748927A (zh) 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用
HK40105889A (zh) 用於制备nlrp3抑制剂的方法
JP2026502847A (ja) Nlrp3阻害剤の調製のためのプロセス
JP2013539760A (ja) 抗ウイルス化合物およびその有用な中間体の調製方法
HK40116804A (en) Glp-1r modulating compounds
CN118234729A (zh) 用于制备双环甘氨酸-脯氨酸化合物和其单环甘氨酸-脯氨酸中间体的方法
HK40085187A (en) Glp-1r modulating compounds
HK40085187B (en) Glp-1r modulating compounds